Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review.

CONCLUSION: Current available therapies have either been nonspecific or had important limitations, including in patients with cardiovascular risk factors. Phase III clinical trials of lasmiditan, rimegepant and ubrogepant all met their primary endpoints, so the options for migraine-targeted acute therapy will likely soon increase. PMID: 31291016 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31291016?dopt=Abstract

Source: Headache - June 30, 2019 Category: Neurology Authors: Moreno-Ajona D, Chan C, Villar-Martínez MD, Goadsby PJ Tags: Headache Source Type: research